+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report by Therapeutic Application, by Clinical Trial Phase, by End-use, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 118 Pages
  • June 2022
  • Region: Global
  • Grand View Research
  • ID: 5390518
Description Jump to:
The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030 and is expected to expand at a CAGR of 22.0% over the forecast period. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse application provided by AI in the field of drug studies is impelling the growth.



Based on the phase of the clinical trial, Phase II dominated the market with a share of 47.2% in 2021 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.

In 2021, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth.

In 2021, based on end-use, pharmaceutical companies accounted for the highest revenue share in the market. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and overall drug discovery process, thereby, impelling the growth.

North America dominated the market and accounted for revenue share of 43.8% in 2021. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies’ outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region.

The AI-based technologies witnessed a surge in their adoption due to the outburst of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient’s data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth.

AI-based Clinical Trials Solution Provider Market Report Highlights

  • The market size is anticipated to be valued at USD 7.8 billion by 2030, owing to various applications provided by AI in the field of clinical trials and the growing adoption of such platforms by pharmaceutical companies.
  • The phase-II trials segment dominated the market in 2021, owing to the increasing number of active drug studies in this phase.
  • The oncology segment dominated the market in 2021, owing to the rising prevalence of cancer and the growing number of drug studies in the oncology field.
  • The pharmaceutical companies segment accounted for the highest revenue share in the market owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players.
  • North America dominated the market and accounted for revenue share of 43.8% in 2021, owing to various factors including the increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation and Scope
1.2 Market Definition
1.3 Research Methodology
1.3.1 Information Procurement
1.3.1.1 Purchased database
1.3.1.2 Internal database
1.3.2 Primary Research
1.4 Research Scope and Assumptions
1.5 List of Data Sources
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
Chapter 3 Global AI-based Clinical Trial Solution Providers Market Variables, Trends, & Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Market Restraint Analysis
3.3 Global AI-based Clinical Trial Solution Providers Market Analysis Tools
3.3.1 Industry Analysis-Porter’s
3.3.1.1 Bargaining power of the suppliers
3.3.1.2 Bargaining power of the buyers
3.3.1.3 Threats of substitution
3.3.1.4 Threats from new entrants
3.3.1.5 Competitive rivalry
3.3.2 PESTEL Analysis
3.3.2.1 Political landscape
3.3.2.2 Economic and Social landscape
3.3.2.3 Technology landscape
3.3.2.4 Legal landscape
3.3.2.5 Technology landscape
3.3.3 Major Deals & Strategic Alliances Analysis
3.4 COVID-19 Impact on the market
Chapter 4 AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis
4.1 Definitions & Scope
4.2 Global AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Market Share Analysis, 2021 and 2030
4.3 Phase-I
4.3.1 Phase-I analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
4.3.2 Phase-II
4.3.2.1 Phase-II analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
4.3.3 Phase-III
4.3.3.1 Phase-III analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
Chapter 5 AI-based Clinical Trial Solution Providers Market: Therapeutic Application Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Global AI-based Clinical Trial Solution Providers Market: Therapeutic Application Market Share Analysis, 2021 and 2030
5.3 Oncology
5.3.1 Oncology analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
5.4 Cardiovascular Diseases
5.4.1 Cardiovascular Diseases analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
5.5 Neurological Diseases or Conditions
5.5.1 Neurological Diseases or Conditions analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
5.6 Metabolic Diseases
5.6.1 Metabolic Diseases analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
5.7 Infectious Diseases
5.7.1 Infectious Diseases analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
5.8 Others
5.8.1 Others analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
Chapter 6 AI-based Clinical Trial Solution Providers Market: End-Use Estimates & Trend Analysis
6.1 Definitions & Scope
6.2 Global AI-based Clinical Trial Solution Providers Market: End-Use Market Share Analysis, 2020 and 2030
6.3 Pharmaceutical Companies
6.3.1 Pharmaceutical Companies analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
6.4 Academia
6.4.1 Academia analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
6.5 Others
6.5.1 Others analysis Market Estimates and Forecasts, 2016-2030 (USD Million)
Chapter 7 AI-based Clinical Trial Solution Providers Market: Regional Estimates & Trend Analysis, By Clinical Trial Phase, Therapeutic Application & End-Use
7.1 Global AI-based Clinical Trial Solution Providers Market: Regional Movement Analysis
7.2 North America
7.2.1 North America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.3 Europe
7.3.1 Europe AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.3.4 Spain
7.3.4.1 Spain AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.3.5 France
7.3.5.1 France AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.3.6 Italy
7.3.6.1 Italy AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.3.7 Russia
7.3.7.1 Russia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.4.2 China
7.4.2.1 China AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.4.3 Japan
7.4.3.1 Japan AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.4.4 India
7.4.4.1 India AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.4.5 South Korea
7.4.5.1 South Korea AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.4.6 Australia
7.4.6.1 Australia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.5 Latin America
7.5.1 Latin America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.6 MEA
7.6.1 MEA AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016-2030 (USD Million)
Chapter 8 Company Profiles
8.1 Unlearn.AI, Inc.
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Saama Technologies
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Antidote Technologies, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Exscientia
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Google Inc. (Verily)
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 IBM Watson
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 GNS Healthcare
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 BioSymetrics
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Euretos
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Koneksa Health
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
8.11 Trials.Ai
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
8.12 Ardigen
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Product Benchmarking
8.12.4 Strategic Initiatives
8.13 Pharmaseal
8.13.1 Company Overview
8.13.2 Financial Performance
8.13.3 Product Benchmarking
8.13.4 Strategic Initiatives
8.14 Halo Health Systems
8.14.1 Company Overview
8.14.2 Financial Performance
8.14.3 Product Benchmarking
8.14.4 Strategic Initiatives
8.15 DEEP LENS AI
8.15.1 Company Overview
8.15.2 Financial Performance
8.15.3 Product Benchmarking
8.15.4 Strategic Initiatives
8.16 CONSILX
8.16.1 Company Overview
8.16.2 Financial Performance
8.16.3 Product Benchmarking
8.16.4 Strategic Initiatives
8.17 AiCure, LLC
8.17.1 Company Overview
8.17.2 Financial Performance
8.17.3 Product Benchmarking
8.17.4 Strategic Initiatives
8.18 BioAge Labs, Inc.
8.18.1 Company Overview
8.18.2 Financial Performance
8.18.3 Product Benchmarking
8.18.4 Strategic Initiatives
8.19 Symphony AI
8.19.1 Company Overview
8.19.2 Financial Performance
8.19.3 Product Benchmarking
8.19.4 Strategic Initiatives
8.20 Median Technologies
8.20.1 Company Overview
8.20.2 Financial Performance
8.20.3 Product Benchmarking
8.20.4 Strategic Initiatives
8.21 Intelligencia
8.21.1 Company Overview
8.21.2 Financial Performance
8.21.3 Product Benchmarking
8.21.4 Strategic Initiatives
8.22 Mendel.ai
8.22.1 Company Overview
8.22.2 Financial Performance
8.22.3 Product Benchmarking
8.22.4 Strategic Initiatives
8.23 Innoplexus
8.23.1 Company Overview
8.23.2 Financial Performance
8.23.3 Product Benchmarking
8.23.4 Strategic Initiatives
8.24 Deep 6 AI
8.24.1 Company Overview
8.24.2 Financial Performance
8.24.3 Product Benchmarking
8.24.4 Strategic Initiatives
8.25 Phesi
8.25.1 Company Overview
8.25.2 Financial Performance
8.25.3 Product Benchmarking
8.25.4 Strategic Initiatives
List of Tables
Table 1 North America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 2 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 3 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 4 U.S. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 5 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 6 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 7 Canada AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 8 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 9 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 10 Europe AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 11 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 12 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 13 U.K. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 14 U.K. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 15 U.K. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 16 Germany AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 17 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 18 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 19 Spain AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 20 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 21 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 22 France AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 23 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 24 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 25 Italy AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 26 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 27 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 28 Russia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 29 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 30 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 31 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 32 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 33 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 34 China AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 35 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 36 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 37 Japan AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 38 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 39 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 40 India AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 41 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 42 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 43 Australia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 44 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 45 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table46 South Korea AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 47 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 48 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 49 Latin America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 50 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 51 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 52 Brazil AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 53 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 54 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 55 Mexico AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 56 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 57 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 58 Argentina AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 59 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 60 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 61 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 62 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 63 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 64 South Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 65 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 66 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 67 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 68 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 69 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
Table 70 UAE AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016-2030 (USD Million)
Table 71 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016-2030 (USD Million)
Table 72 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016-2030 (USD Million)
List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 AI-based Clinical Trial Solution Providers market snapshot, 2021, (USD Million)
Fig. 6 AI-based Clinical Trial Solution Providers market trends & outlook
Fig. 7 Penetration & growth prospect mapping
Fig. 8 Market driver analysis (Current & future impact)
Fig. 9 Market restraint analysis (Current & future impact)
Fig. 10 AI-based Clinical Trial Solution Providers market, clinical trial phase outlook key takeaways (USD Million)
Fig. 11 AI-based Clinical Trial Solution Providers market: clinical trial phase movement analysis (USD Million), 2021 & 2030
Fig. 12 Phase-I Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 13 Phase-II Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 14 Phase-III Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 15 AI-based Clinical Trial Solution Providers market, therapeutic application outlook key takeaways (USD Million)
Fig. 16 AI-based Clinical Trial Solution Providers market: therapeutic application movement analysis (USD Million), 2020 & 2030
Fig. 17 Oncology Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 18 Cardiovascular diseases Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 19 Neurological Diseases or Conditions Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 20 Metabolic Diseases Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 21 Infectious Diseases Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 22 Other Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 23 AI-based Clinical Trial Solution Providers market, end-use outlook key takeaways (USD Million)
Fig. 24 AI-based Clinical Trial Solution Providers market: end-use movement analysis (USD Million), 2020 & 2030
Fig. 25 Pharmaceutical companies Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 26 Academia Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 27 Others Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 28 AI-based Clinical Trial Solution Providers market, regional outlook key takeaways (USD Million)
Fig. 29 AI-based Clinical Trial Solution Providers market: regional movement analysis (USD Million), 2020 & 2030
Fig. 30 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 31 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 32 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 33 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 34 U.K AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 35 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 36 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 37 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 38 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 39 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 40 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 41 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 42 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 43 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 44 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 45 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 46 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 47 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 48 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 49 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 50 MEA AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 51 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 52 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)
Fig. 53 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016-2030 (USD Million)

Companies Mentioned

  • Unlearn.AI, Inc.
  • Saama Technologies
  • Antidote Technologies, Inc.
  • Exscientia
  • Google Inc. (Verily)
  • IBM Watson
  • GNS Healthcare
  • BioSymetrics
  • Euretos
  • Koneksa Health
  • Trials.Ai
  • Ardigen
  • Pharmaseal
  • Halo Health Systems
  • DEEP LENS AI
  • CONSILX
  • AiCure, LLC
  • BioAge Labs, Inc.
  • Symphony AI
  • Median Technologies
  • Intelligencia
  • Mendel.ai
  • Innoplexus
  • Deep 6 AI
  • Phesi

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages118
PublishedJune 2022
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 1.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.8 Billion
Compound Annual Growth Rate22.0%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Global AI-based Clinical Trials Solution Provider Market Analysis & Forecast to 2024-2034: Market By Clinical Trial Phase; By Therapeutic Application; By End-user; and By Region - Product Image

Global AI-based Clinical Trials Solution Provider Market Analysis & Forecast to 2024-2034: Market By Clinical Trial Phase; By Therapeutic Application; By End-user; and By Region

  • Report
  • 200 Pages
  • Global
From
AI in Clinical Trials Market (2nd Edition): AI Software and Service Providers - Distribution by Trial Phase, Target Therapeutic Area, End-user and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035 - Product Image

AI in Clinical Trials Market (2nd Edition): AI Software and Service Providers - Distribution by Trial Phase, Target Therapeutic Area, End-user and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 304 Pages
  • Global
From
AI-based Clinical Trial Solution Providers Market Report 2023-2033 - Product Image

AI-based Clinical Trial Solution Providers Market Report 2023-2033

  • Report
  • 274 Pages
  • Global
From
AI-based Clinical Trial Solution Providers Global Market Report 2024 - Product Image

AI-based Clinical Trial Solution Providers Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Global AI-based Clinical Trials Market by Component (Services, Software), Function (Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening), Phase, Technology, Application, End-user - Forecast 2024-2030 - Product Image

Global AI-based Clinical Trials Market by Component (Services, Software), Function (Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening), Phase, Technology, Application, End-user - Forecast 2024-2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.